



PROVIDER UPDATE

Alert: Norditropin® Drug Shortage

Norditropin is on a drug shortage due to manufacturing and supply chain delays. Norditropin is a therapy often prescribed for patients with growth-related conditions.

Providers should prescribe Genotropin instead of Norditropin for:

- Patients that have received a prior authorization approval for Norditropin therapy but are having trouble obtaining it.
- New patients who and have not received a prior authorization approval for Norditropin and are experiencing barriers in obtaining the medication.
 - Genotropin will require a prior authorization.

As a reminder, **both Norditropin and Genotropin require a prior authorization** and are on the HHO Preferred Drug List.

Norditropin supply will restart in mid-March and continue through April, May, and June. Norditropin demand is expected to be met by the end of June and remain stable throughout the second half of this year.

Other somatotropin injection products do not appear to be impacted by this shortage.

For more information on the Norditropin shortage, visit hho.fyi/fda-drug-shortage.

Questions? Contact Pharmacy Services at 1-844-325-6251, Monday – Friday, 8 a.m. – 5 p.m.